Next Article in Journal
Beyond Gene Delivery: Strategies to Engineer the Surfaces of Viral Vectors

Biomedicines—Moving Biologic Agents into Approved Treatment Options

Department of Medical and Molecular Genetics, Indiana University School of Medicine, 975 W, Walnut Street Room 130, Indianapolis, IN 46202, USA
Biomedicines 2013, 1(1), 1-2;
Received: 8 March 2013 / Accepted: 8 March 2013 / Published: 11 March 2013
Note: In lieu of an abstract, this is an excerpt from the first page.

The development of biologic agents for therapeutic purposes, or biomedicines, has seen an active area of research both at the bench and in clinical trials. There is mounting evidence that biologic products can provide effective therapy for diseases that have been unresponsive to traditional pharmacologic approaches. Monoclonal antibody therapy for cancer and rheumatologic diseases has become a well accepted part of disease treatment plans. Gene therapy products have been approved in China and Europe. Bioengineering of new agents capitalizing on microRNA biology, nanoparticle technology, stem cell biology, and an increasing understanding of immunology predict a rich future for product development. [...] View Full-Text
MDPI and ACS Style

Cornetta, K. Biomedicines—Moving Biologic Agents into Approved Treatment Options. Biomedicines 2013, 1, 1-2.

AMA Style

Cornetta K. Biomedicines—Moving Biologic Agents into Approved Treatment Options. Biomedicines. 2013; 1(1):1-2.

Chicago/Turabian Style

Cornetta, Kenneth. 2013. "Biomedicines—Moving Biologic Agents into Approved Treatment Options" Biomedicines 1, no. 1: 1-2.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop